Analyst Research Report Snapshot

Title:

Fortis Healthcare (FORH) - Qtr. Update - Dated - May 31, 2013

Price:

$35.00

Provider:

Axis Capital Limited

Date:

31 May 2013

Pages:

4

Type:

AcrobatPDF

Companies referenced:

FOHE.NS

Available for Immediate Download
Summary:

Fortis Healthcare (FHL) is deleveraging its balance sheet. We expect debt: equity to come down to 0.6x in FY14 (vs. 1.1x in FY13): (a) Sale of Dental Corp (DC), Australia for AUD $ 270 mn; proceeds received in Q1FY14 (expected in FY13 earlier) and (b) Rs 3.2 bn raised via the recent IPP. Deleveraging (resulting in lower interest cost) coupled with higher number of maturing beds and better margin at SRL Diagnostics to drive turnaround in FY15E. Post DC sell-off, India (hospitals and diagnostics) would contribute 70% of total revenue (50% currently). Management guidance of 2,000 bed additions over next 3 years would be driven by RHT (asset light with capex of Rs 2.5 bn p.a) and ~10% ARPOB growth. Estimates and valuation:  We estimate marginal loss in FY14 (PAT of Rs 350 mn expected earlier) to factor in higher interest outgo due to delay in DC sale proceeds. We lower our FY15E EPS to Rs 2.4 (Rs 3 earlier) due to faster roll-out of beds leading to higher set-up cost and service fee  We reduce our DCF-based target price to Rs 119 (Rs 125 earlier). Maintain BUY given 34% upside from CMP of Rs 89 Regards, Kashyap Pujara (ED – Midcaps) Institutional Equity Research Axis Capital Ltd Tel: +91 22 4325 1146 Farzan Madon (VP – Midcaps) Institutional Equity Research Axis Capital Ltd Tel: +91 22 4325 1131

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.